Primecap Management Company Decreased Its Stake in Biogen INC (BIIB) by $32.97 Million; Shares Declined

May 16, 2018 - By Margaret Guttierez

Biogen Inc. (NASDAQ:BIIB) Corporate LogoDuring Q4 2017 the big money sentiment increased to 1.17. That’s change of 0.04, from 2017Q3’s 1.13. 46 investors sold all, 305 reduced holdings as BIIB ratio is positive. 305 increased holdings while 105 funds took holdings. Funds hold 180.65 million shares thus 0.28% less from 2017Q3’s 181.16 million shares. Seaward Partnership holds 0.01% or 843 shs in its capital. South Dakota Investment Council owns 45,395 shs. Commonwealth Comml Bank Of Aus invested in 21,133 shs. Compton Mngmt Inc Ri reported 1,008 shs or 0.14% of all its holdings. Grp Inc One Trading LP owns 10,566 shs. Exxonmobil Inv Mngmt Tx holds 0.29% of its capital in Biogen Inc. (NASDAQ:BIIB) for 33,619 shs. Fort Washington Inv Advisors Inc Oh owns 1.22% invested in Biogen Inc. (NASDAQ:BIIB) for 385,209 shs. Girard Partners Ltd invested in 0.05% or 821 shs. 1,565 are owned by Fulton Bank & Trust Na. Oregon Pub Employees Retirement Fund has invested 0.29% of its capital in Biogen Inc. (NASDAQ:BIIB). Tru Com Of Toledo Na Oh has invested 0.05% in Biogen Inc. (NASDAQ:BIIB). Mufg Americas accumulated 0.1% or 10,499 shs. Gmt Corp holds 2.07% or 319,100 shs. Duff And Phelps Invest Mngmt Com has 0.01% invested in Biogen Inc. (NASDAQ:BIIB). Horan Capital Management has 23,166 shs.

BIIB had 5 insider sales and 1 buying transaction since January 9, 2018. This’s net activity of $10.09 million. The insider PANGIA ROBERT W sold 5,832 shs worth $1.92 million. $266,444 worth of Biogen Inc. (NASDAQ:BIIB) shs were sold by Sandrock Alfred.

In Biogen Inc. (BIIB) was reduced the stake owned by Primecap Management Company. The reduction is 0.68% according to 2017Q4 SEC filling. 103,683 shares were sold by Primecap Management Company as the company’s stock declined 17.01% with the market. The institutional investor is holding 15.11 million shares, compared to the 15.21 million from the previous quarter. And the reported value of the biological products (no diagnostic substances) company is $4.81B for the 2017Q4. $59.58B is the MC of Biogen Inc.. The stock increased 2.27% or $6.28 during the last trading session, touching $282.34.Currently Biogen Inc. is downtrending after 3.66% change in last May 16, 2017. BIIB has 1.05M shares volume. The stock underperformed the S&P 500 by 15.21%.

Primecap Management Company manages about $87.86B and $130.31 billion US Long portfolio. It upped its stake in Hawaiian Holdings Inc. (NASDAQ:HA) by 110,000 shares to 751,300 shares, valued at $29.94 million in 2017Q4, according to the filing. Primecap Management Company has risen its stake in Ericsson (NASDAQ:ERIC) and also increased its holding in Boston Scientific Corp (NYSE:BSX) by 1.71 million shares in the quarter, for a total of 43.88 million shares.

On July, 24. Investors expect Biogen Inc. (NASDAQ:BIIB) to publish its quarterly earnings, Faxor reports. Last year’s earnings per share was $5.04, while now analysts expect change of 5.56 % up from current $5.32 earnings per share. If BIIB’s EPS is $5.32 the profit will be $1.12B for 13.27 P/E. After $6.05 earnings per share was reported last quarter, analysts now see negative EPS growth of -12.07 % for Biogen Inc..

For more Biogen Inc. (NASDAQ:BIIB) news released briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Fool.com or Seekingalpha.com. The titles are as follows: “Biogen Buy Signal: Alzheimer’s Royalties Option” released on May 02, 2018, “Biogen’s Ionis Deal Is Brilliant” on April 25, 2018, “Biogen Q1 2018: Too Cheap To Ignore” with a publish date: April 25, 2018, “Better Buy: Amgen Inc. vs. Biogen Inc.” and the last “Biogen: Down Too Far, Too Fast?” with publication date: April 25, 2018.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

A total of 25 analysts rate Biogen Inc (NASDAQ:BIIB) as follows: 17 “Buy”, 8 “Hold” and 0 “Sell”. Тherefore 68% are bullish. (NASDAQ:BIIB) has 43 ratings reports on May 16, 2018 according to StockzIntelligence. On Wednesday, April 25 the rating was maintained by Leerink Swann with “Hold”. On Friday, January 26 H.C. Wainwright maintained Biogen Inc. (NASDAQ:BIIB) with “Buy” rating. On Tuesday, April 24 the stock of Biogen Inc. (NASDAQ:BIIB) has “Hold” rating given by Jefferies. On Monday, November 27 the firm has “Buy” rating by BMO Capital Markets given. On Thursday, January 25 the rating was maintained by Cantor Fitzgerald with “Hold”. In Friday, January 26 report Deutsche Bank maintained the stock with “Buy” rating. On Wednesday, January 31 the firm has “Buy” rating given by UBS. On Friday, January 26 the stock of Biogen Inc. (NASDAQ:BIIB) earned “Buy” rating by Oppenheimer. On Thursday, January 25 the stock of Biogen Inc. (NASDAQ:BIIB) earned “Hold” rating by Robert W. Baird. On Wednesday, January 24 Canaccord Genuity maintained Biogen Inc. (NASDAQ:BIIB) rating. Canaccord Genuity has “Hold” rating and $350 target.

Biogen Inc. (NASDAQ:BIIB) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: